Core Insights - The article discusses the transformative potential of biomanufacturing, which utilizes microorganisms to create sustainable products, thereby reducing reliance on fossil fuels and minimizing environmental impact [1][2][4]. Group 1: Biomanufacturing Overview - Biomanufacturing is defined as a process where microorganisms convert renewable resources into valuable products, such as biodegradable plastics and high-performance materials [2][3]. - The shift from traditional petrochemical-based production to biomanufacturing is seen as essential for achieving a more sustainable industrial model [2][4]. Group 2: Economic Impact and Market Potential - The biomanufacturing industry in China is approaching a total scale of nearly 1 trillion yuan, driven by policy support and capital investment [6]. - Utilizing agricultural waste, such as crop straw, could potentially generate over 1 million tons of biodegradable plastic annually, creating a market worth hundreds of billions [5][6]. Group 3: Industry Development and Collaboration - Companies like Kasei Biotech are forming strategic partnerships to develop biobased materials, demonstrating a collaborative approach to building a competitive biomanufacturing ecosystem [7]. - The integration of biomanufacturing in various sectors, including healthcare and consumer products, is expanding, with companies innovating in areas like biodegradable medical materials and low-sugar food products [8]. Group 4: Challenges and Barriers - The biomanufacturing sector faces challenges in scaling up from laboratory to industrial production, particularly in optimizing microbial strains and production processes [9][10]. - Regulatory hurdles and slow approval processes for genetically engineered strains hinder the speed of innovation and market entry for new biomanufactured products [9][10].

Core Viewpoint - On November 25, 2023, a block trade of Kaisa Bio occurred with a volume of 1.1243 million shares, amounting to 43.2406 million yuan, at a price of 38.46 yuan, representing a discount of 20.85% compared to the closing price of the day [2] Trading Activity Summary - The block trade involved a total volume of 1.1243 million shares and a transaction amount of 43.2406 million yuan, with a transaction price of 38.46 yuan, reflecting a discount of 20.85% relative to the closing price of the day [2] - The buyer and seller for this transaction were both from Changcheng Securities Co., Ltd., Chongqing Xinnan Road Securities Business Department [2] Stock Performance Summary - Kaisa Bio's closing price on the same day was 48.59 yuan, which increased by 1.08%, with a turnover rate of 0.59% and a total transaction amount of 169 million yuan [2] - The stock experienced a net outflow of 369,100 yuan in main funds throughout the day, and over the past five days, the stock has cumulatively decreased by 2.17%, with a total net outflow of 27 million yuan [2] Margin Trading Summary - The latest margin financing balance for Kaisa Bio is 598 million yuan, which has increased by 42.0896 million yuan over the past five days, reflecting a growth rate of 7.57% [2] Company Background - Shanghai Kaisa Bio Technology Co., Ltd. was established on November 24, 2000, with a registered capital of 7.21289794 billion yuan [2]

Core Viewpoint - Kasei Biotech's wholly-owned subsidiary, Anhui Hexian, is focused on the research, production, and sales of bio-based polyamide modified resins, with applications in various sectors including automotive piping, passenger vehicle interiors and exteriors, low-voltage electrical appliances, and composite materials. The facility is currently in the equipment installation and debugging phase and has not yet commenced production [1]. Group 1 - Anhui Hexian is a wholly-owned subsidiary of Kasei Biotech [1] - The company specializes in bio-based polyamide modified resins [1] - Applications for the products include automotive piping and passenger vehicle interiors and exteriors [1] Group 2 - The facility is currently in the installation and debugging phase [1] - Production has not yet started [1]

Group 1 - The company announced that all directors unanimously agreed to elect Ms. Zang Huiqing as the vice chairman of the third board of directors [2]

公司董事会于近日收到董事长、总裁 XIUCAI LIU（刘修才）先生递交的辞 去公司总裁职位的书面报告。XIUCAI LIU（刘修才）先生辞去总裁职务后，仍继 续担任董事长、董事会战略委员会召集人、董事会提名委员会成员以及公司首席 科学家的职务，将主要精力投入到公司战略规划、重大项目推动以及高端人力培 养等方面。 证券代码：688065 证券简称：凯赛生物 公告编号：2025-063 上海凯赛生物技术股份有限公司 关于高级管理人员变更及选举副董事长的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、高级管理人员离任情况 （一）提前离任的基本情况 特此公告。 上海凯赛生物技术股份有限公司 董事会 | 姓名 | 离任职务 | 离任时间 | 原定任期 到期日 | 离任原因 | 是否继续在上 市公司及其控 股子公司任职 | 具体职务 | 是否存在 未履行完 毕的公开 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | | 承诺 | | XIUCAI ...

Core Viewpoint - The company announces the resignation of its President Liu Xiucai due to strategic development needs, effective November 20, 2025, while he will continue to serve as Chairman and Chief Scientist [1] Group 1: Leadership Changes - Liu Xiucai resigns as President but retains roles as Chairman, Strategic Committee convener, Nomination Committee member, and Chief Scientist [1] - Yang Chen has been appointed as the new President, with a term aligned with the current board [1] - Zang Huiqing has been elected as Vice Chairman, serving until the current board's term ends [1]

Core Viewpoint - Kasei Biotech (688065) announced the resignation of its President Liu Xiucai due to strategic development needs, effective November 20, 2025, while he will continue to serve as Chairman and Chief Scientist [1] Company Leadership Changes - Liu Xiucai will focus on strategic planning, major project promotion, and high-end talent cultivation after resigning as President [1] - Yang Chen has been appointed as the new President, with a term aligned with the current board [1] - Zang Huiqing has been elected as Vice Chairman, serving until the current board's term ends [1]

证券代码：688065 证券简称：凯赛生物 公告编号：2025-062 上海凯赛生物技术股份有限公司 2025 年员工持股计划第一次持有人会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、持有人会议召开情况 上海凯赛生物技术股份有限公司（以下简称"公司"）于 2025 年 11 月 18 日以通讯及邮件的方式召开了 2025 年员工持股计划（以下简称"本员工持股计 划"）第一次持有人会议（以下简称"持有人会议"或"会议"）。会议应出席 首次授予部分持有人 124 名，实际出席首次授予部分持有人 121 名，代表公司本 员工持股计划首次授予部分份额 2,902.76 万份，占公司本员工持股计划首次授 予部分总份额 2,935.95 万份的 98.87%。会议由董事会秘书臧慧卿女士召集主持， 本次会议的召集、召开及表决程序符合相关法律法规、规范性文件及本员工持股 计划的相关规定，会议合法有效。 二、持有人会议审议情况 经与会持有人逐项审议，通过如下议案： （一）审议通过《关于设立公司 2025 年员工持股计划管 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 公司将持续关注本员工持股计划的实施进展情况，并按照相关法律法规的规 定及时履行信息披露义务。敬请广大投资者注意投资风险。 特此公告。 上海凯赛生物技术股份有限公司（以下简称"公司"）于 2025 年 9 月 29 日 召开了第三届董事会第二次会议，并于 2025 年 10 月 15 日召开了 2025 年第三次 临时股东会，会议审议通过了《关于<公司 2025 年员工持股计划（草案）>及其 摘要的议案》等相关议案。具体内容详见公司于 2025 年 9 月 30 日和 2025 年 10 月 16 日刊登在上海证券交易所网站（www.sse.com.cn）及指定信息披露媒体上 的相关公告。 根据《关于上市公司实施员工持股计划试点的指导意见》及《上海证券交易 所科创板上市公司自律监管指引第 1 号——规范运作》的相关规定，现将公司 2025 年员工持股计划（以下简称"本员工持股计划"）的实施进展情况公告如 下： 根据本员工持股计划首次授予部分参与对象实际认购和最终缴款的查验结 果 ...

Group 1 - The chemical sector experienced a significant drop on November 17, with the chemical ETF (516020) initially rising by 1.69% before falling to a decrease of 0.24% at the time of reporting [1] - Key stocks in the sector, including coatings, battery chemicals, and fluorochemicals, saw notable declines, with SanKeTree dropping over 3%, and Enjie and Sanmei both falling over 2% [1] - The report indicates that the peak of new capacity additions in the chemical industry has passed, leading to a reduction in capital expenditure, which is expected to improve the supply-demand balance in the sector [1][3] Group 2 - The current PB-LF valuation of the basic chemical industry is close to the bottom levels seen in 2019 and 2024, indicating that the sector is still undervalued [3] - The chemical industry is expected to see a continuous improvement in supply-demand dynamics, with a potential upward trend in industry prosperity [3] - Analysts suggest that the chemical sector may experience a rebound starting in 2026, driven by improved domestic demand and supply-side adjustments [3] Group 3 - The chemical ETF (516020) tracks the CSI segmented chemical industry index, covering various sub-sectors, with nearly 50% of its holdings in large-cap leading stocks [4] - Investors can also access the chemical ETF through linked funds, providing a more efficient way to invest in the chemical sector [4]